Created at Source Raw Value Validated value
Nov. 16, 2021, 6:30 p.m. usa

pregnant or lactating treatment with covid-19 antiviral such as remdesivir or sars-cov-2 antibodies prior covid-19 vaccination or prior recovery from documented covid-19 infection severe or critical covid-19, as indicated by respiratory distress or shortness of breath at rest; resp rate ≥30/min; heart rate ≥125/min; spo2 ≤ 93% on room air or pao2/fio2 ≤ 300 if on supplemental o2 positive hiv or positive hepatitis panel treatment with any medications known to be strongly metabolized by cyp3a4 or cyp2d6

pregnant or lactating treatment with covid-19 antiviral such as remdesivir or sars-cov-2 antibodies prior covid-19 vaccination or prior recovery from documented covid-19 infection severe or critical covid-19, as indicated by respiratory distress or shortness of breath at rest; resp rate ≥30/min; heart rate ≥125/min; spo2 ≤ 93% on room air or pao2/fio2 ≤ 300 if on supplemental o2 positive hiv or positive hepatitis panel treatment with any medications known to be strongly metabolized by cyp3a4 or cyp2d6

April 16, 2021, 12:31 a.m. usa

1. pregnant or lactating 2. treatment with covid-19 antiviral such as remdesivir or sars-cov-2 antibodies 3. prior covid-19 vaccination or prior recovery from documented covid-19 infection 4. severe or critical covid-19, as indicated by respiratory distress or shortness of breath at rest; resp rate ≥30/min; heart rate ≥125/min; spo2 ≤ 93% on room air or pao2/fio2 ≤ 300 if on supplemental o2 5. positive hiv or positive hepatitis panel 6. treatment with any medications known to be strongly metabolized by cyp3a4 or cyp2d6

1. pregnant or lactating 2. treatment with covid-19 antiviral such as remdesivir or sars-cov-2 antibodies 3. prior covid-19 vaccination or prior recovery from documented covid-19 infection 4. severe or critical covid-19, as indicated by respiratory distress or shortness of breath at rest; resp rate ≥30/min; heart rate ≥125/min; spo2 ≤ 93% on room air or pao2/fio2 ≤ 300 if on supplemental o2 5. positive hiv or positive hepatitis panel 6. treatment with any medications known to be strongly metabolized by cyp3a4 or cyp2d6